Evidence map›Paper›PMID 42196910›Full record

ReviewDiagnostics (Basel, Switzerland)2026

Machine Learning Applications for Risk Stratification in Heart Failure with Preserved Ejection Fraction: A New Era in Cardiology.

Bodour S Rajab

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bodour S RajabDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0002-3874-9434

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a prevalent and heterogeneous syndrome with limited therapeutic options, making accurate risk stratification essential yet challenging. Traditional tools such as the H2FPEF and HFA-PEFF scores incorporate few variables and demonstrate modest prognostic performance. Machine learning (ML) offers enhanced risk prediction by integrating multidimensional clinical, imaging, biomarker, and molecular data. This review summarizes current ML applications in HFpEF, including random forests, gradient boosting, support vector machines, and deep learning, highlighting their superior discrimination and ability to reveal phenotypic subgroups with distinct outcomes. We also address practical considerations such as interpretability, real-world validation, and integration into clinical workflows, as well as challenges related to data bias, generalizability, and regulatory requirements. Future opportunities include real-time clinical decision support, digital health integration, and interventional ML to guide personalized therapy. ML holds significant potential to advance precision care and improve outcomes in HFpEF.

Indexed as

heart failuremachine learningphenotypingprecision carerisk prediction

Identifiers

PMID42196910
PMCPMC13205302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.